Natco Pharma Ltd. Financials: Quarterly Results
Revenue
1463
Cr.
PAT
517.90
Cr.
EBITDA
626.80
Cr.
Natco Pharma Ltd. Q2FY26 Financial Metrics
| Indicator | Sep-25 | Jun-25 | Mar-25 | Dec-24 | Sep-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 1363 | 1328.90 | 1221 | 474.80 | 1371.10 |
| Total Income From Operations (Cr.) | 1363 | 1328.90 | 1221 | 474.80 | 1371.10 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 626.80 | 575.10 | 516.10 | 168.10 | 822.30 |
| P/L Before Exceptional Items & Tax (Cr.) | 613.70 | 571.90 | 505.90 | 163.70 | 818.20 |
| P/L After Tax from Ordinary Activities (Cr.) | 517.90 | 480.30 | 406 | 132.40 | 676.50 |
| Net Profit/Loss For the Period (Cr.) | 517.90 | 480.30 | 406 | 132.40 | 676.50 |
| Basic EPS | 28.94 | 26.84 | 22.70 | 7.43 | 37.81 |
FAQs
Natco Pharma Ltd. announced its quarterly results for Q2 FY2026 on November 14, 2025.
In Q2 FY2026, Natco Pharma Ltd. are as follows:
Revenue: ₹1463 crore
Net Profit: ₹517.90 crore.
For Q2 FY2026, Natco Pharma Ltd. posted ₹1463 crore in revenue and ₹517.90 crore in net profit.
Past quarterly results for Natco Pharma Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.